Tonix Pharmaceuticals (TNXP) said Wednesday it submitted a new drug application to the US Food and Drug Administration for TNX-102 SL, an investigational drug in development to treat fibromyalgia.
TNX-102 SL showed a "statistically significant reduction" in pain linked with fibromyalgia in two phase 3 studies and was generally well tolerated, the company said.
The investigational drug was given fast track designation for fibromyalgia by the FDA in July, Tonix said.
Tonix said that, if the regulator accepts the new drug application for review, it expects a 2025 date for an approval decision, based on the Prescription Drug User Fee Act.
The company's shares were rising past 3% in recent trading.
Price: 0.15, Change: +0.01, Percent Change: +3.55
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.